



REFERENCES

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders 5th ed.*; 2013.

American Psychiatric Association. Learn About the Collaborative Care Model. Accessed April 17, 2024. <https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care/learn>

American Psychiatric Association. Position Statement on Screening and Treatment of Mood and Anxiety Disorders During Pregnancy and Postpartum. 2018. Accessed May 23, 2024. <https://www.psychiatry.org/getattachment/c5db4e7b-6405-4655-aecb-bc79d5efb4ea/Position-Screening-and-Treatment-Mood-Anxiety-Disorders-During-Pregnancy-Postpartum.pdf>

Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf.* 2009;18(3):246-252.

Antonoudiou P, Colmers PLW, Walton NL, et al. Allopregnanolone mediates affective switching through modulation of oscillatory states in the basolateral amygdala. *Biol Psychiatry.* 2022;91(3):283-293.

Beck CT. Revision of the postpartum depression predictors inventory. *J Obstet Gynecol Neonatal Nurs.* 2002;31(4):394-402.

Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. *Br J Clin Pharmacol.* 2016;81(4):589-604.

Betcher HK, Wisner KL. Psychotropic treatment during pregnancy: Research synthesis and clinical care principles. *J Womens Health (Larchmt).* 2020;29(3):310-318.

Brown JVE, Wilson CA, Ayre K, et al. Antidepressant treatment for postnatal depression. *Cochrane Database Syst Rev.* 2021;2(2):CD013560.

Carter FA, Carter JD, Luty SE, Wilson DA, Frampton CM, Joyce PR. Screening and treatment for depression during pregnancy: a cautionary note. *Aust N Z J Psychiatry.* 2005;39(4):255-261.

Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med.* 2006;354(6):579-587.

Chan J, Natekar A, Einarson A, Koren G. Risks of untreated depression in pregnancy. *Can Fam Physician.* 2014;60(3):242-243.

Chapman SL, Wu LT. Postpartum substance use and depressive symptoms: a review. *Women Health.* 2013;53(5):479-503.

Chechko N, Losse E, Frodl T, Nehls S. Baby blues, premenstrual syndrome and postpartum affective disorders: intersection of risk factors and reciprocal influences. *BJPsych Open.* 2023;10(1):e3.



Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry*. 1987;150:782-786.

Dama MH, Van Lieshout RJ. Perinatal depression: A guide to detection and management in primary care. *J Am Board Fam Med*. 2024;36(6):1071-1086.

Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: A randomized clinical trial [published correction appears in *JAMA Psychiatry*. 2022 Jul 1;79(7):740] [published correction appears in *JAMA Psychiatry*. 2023 Feb 1;80(2):191]. *JAMA Psychiatry*. 2021;78(9):951-959.

Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the treatment of postpartum depression. *Am J Psychiatry*. 2023;180(9):668-675.

Deligiannidis KM, Vaughn R. Staying up to date with evolving postpartum depression pathophysiology and treatment research. *J Clin Psychiatry*. 2023;84(4):sagppd3003sho.

Earls MF, Yogman MW, Mattson G, Rafferty J; Committee on Psychosocial Aspects of Child and Family Health. Incorporating recognition and management of perinatal depression into pediatric practice. *Pediatrics*. 2019;143(1):e20183259.

Edinoff AN, Odisho AS, Lewis K, et al. Brexanolone, a GABA_A modulator, in the treatment of postpartum depression in adults: A comprehensive review. *Front Psychiatry*. 2021;12:699740.

Field T. Postpartum depression effects on early interactions, parenting, and safety practices: a review. *Infant Behav Dev*. 2010;33(1):1-6.

Garafola S, Shiferaw E, Dev V. Safety of brexanolone in adults with postpartum depression: Postmarketing surveillance data. *Drugs Real World Outcomes*. 2023;10(3):351-356.

Goodman JH. Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. *Birth*. 2009;36(1):60-69.

Grace SL, Evindar A, Stewart DE. The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. *Arch Womens Ment Health*. 2003;6(4):263-274.

Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. *Arch Gen Psychiatry*. 2010;67(10):1012-1024.

Guide to Community Preventive Services. Mental Health and Mental Illness: Collaborative Care for the Management of Depressive Disorders. November 3, 2018. Accessed April 17, 2024.

<https://www.thecommunityguide.org/findings/mental-health-and-mental-illness-collaborative-care-management-depressive-disorders.html>



ELEVATING PATIENT CARE: EARLY DETECTION AND EVIDENCE-BASED PHARMACOTHERAPY FOR POSTPARTUM DEPRESSION IN PRIMARY CARE

Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. *Am J Psychiatry*. 2000;157(11):1873-1875.

Jacob TC, Moss SJ, Jurd R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. *Nat Rev Neurosci*. 2008;9(5):331-343.

Justesen K, Jourdaine D. Peripartum depression: Detection and treatment. *Am Fam Physician*. 2023;108(3):267-272.

Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf*. 2008;17(8):801-806.

Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. *Lancet*. 2017;390(10093):480-489.

Ko JY, Rockhill KM, Tong VT, Morrow B, Farr SL. Trends in postpartum depressive symptoms - 27 states, 2004, 2008, and 2012. *MMWR Morb Mortal Wkly Rep*. 2017;66(6):153-158.

Liu C, Ystrom E, McAdams TA. Long-term maternal and child outcomes following postnatal SSRI treatment. *JAMA Netw Open*. 2023;6(8):e2331270.

Meltzer-Brody S, Stuebe A. The long-term psychiatric and medical prognosis of perinatal mental illness. *Best Pract Res Clin Obstet Gynaecol*. 2014;28(1):49-60.

Meltzer-Brody S, Colquhoun H, Riesenber R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials [published correction appears in *Lancet*. 2018;392(10153):1116]. *Lancet*. 2018;392(10152):1058-1070.

Meltzer-Brody S, Kanes SJ. Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. *Neurobiol Stress*. 2020;12:100212.

Moore Simas TA, Whelan A, Byatt N. Postpartum depression-New screening recommendations and treatments. *JAMA*. 2023;330(23):2295-2296.


Pearlstein T. Depression during pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2015;29(5):754-764.

Putnick DL, Sundaram R, Bell EM, et al. Trajectories of maternal postpartum depressive symptoms. *Pediatrics*. 2020;146(5):e20200857.

Reddy DS, Estes WA. Clinical potential of neurosteroids for CNS disorders. *Trends Pharmacol Sci*. 2016;37(7):543-561.

Roubinov D, Musci RJ, Hipwell AE, et al. Trajectories of depressive symptoms among mothers of preterm and full-term infants in a national sample. *Arch Womens Ment Health*. 2022;25(4):807-817.

Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4. *Obstet Gynecol*. 2023;141(6):1232-1261.



ELEVATING PATIENT CARE: EARLY DETECTION AND EVIDENCE-BASED PHARMACOTHERAPY FOR POSTPARTUM DEPRESSION IN PRIMARY CARE

Sharma V, Sharma P. Postpartum depression: diagnostic and treatment issues. *J Obstet Gynaecol Can.* 2012;34(5):436-442.

Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes [published correction appears in *Womens Health (Lond)*. 2019;15:1745506519854864]. *Womens Health (Lond)*. 2019;15:1745506519844044.

Smith MV, Shao L, Howell H, Wang H, Poschman K, Yonkers KA. Success of mental health referral among pregnant and postpartum women with psychiatric distress. *Gen Hosp Psychiatry.* 2009;31(2):155-162.

U.S. Preventive Services Task Force, Barry MJ, Nicholson WK, et al. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2023;329(23):2057-2067.

Viguera AC, Emmerich AD, Cohen LS. Case records of the Massachusetts General Hospital. Case 24-2008. A 35-year-old woman with postpartum confusion, agitation, and delusions. *N Engl J Med.* 2008;359(5):509-515.

Viguera AC, McElheny SA, Caplin PS, et al. Risk of poor neonatal adaptation syndrome among infants exposed to second-generation atypical antipsychotics compared to antidepressants: Results from the National Pregnancy Registry for Psychiatric Medications. *J Clin Psychiatry.* 2023;84(1):22m14492.

Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. *Am J Perinatol.* 2011;28(1):19-24.

Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. *Am J Psychiatry.* 2009;166(5):557-566.

Wisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. *JAMA Psychiatry.* 2013;70(5):490-498.

Yawn BP, Pace W, Wollan PC, et al. Concordance of Edinburgh Postnatal Depression Scale (EPDS) and Patient Health Questionnaire (PHQ-9) to assess increased risk of depression among postpartum women. *J Am Board Fam Med.* 2009;22(5):483-491.

Yawn BP, Dietrich AJ, Wollan P, et al. TRIPPD: a practice-based network effectiveness study of postpartum depression screening and management. *Ann Fam Med.* 2012;10(4):320-329.

Zurzuva. Prescribing Information. Sage Therapeutics, Inc. Accessed May 13, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217369s000lbl.pdf